000			04220cam a2200361 a 4500
999			_c4650 _d4650
001			17148631
003			SUN
005			20180907123138.0
008			111212s2011 enk b 000 0 eng d
010			_a 2012358826
020			_a9781905783571
020			_a1905783574
035			_a(OCoLC)ocn772592974
040			_aYDXCP _cSUNLIB _dCGU _dCDX _dBWK _dDLC
042			_alccopycat
050	0	0	_aK1519.B54 _bI567 2011
082	0	4	_a346.048/ _bPAU
245	0	0	_aIntellectual property in the life sciences : _ba global guide to rights and their applications / _cconsulting editor, Paul England.
246	3		_aIP in the life sciences
260			_aLondon : _bGlobe Law and Business, _cc2011.
300			_a404 p. ; _c24 cm.
504			_aIncludes bibliographical references.
505	0		_aAn introduction to international intellectual property instruments relevant to life sciences / Nick Bassil -- An introduction to European intellectual property rights / Scott Parker, Adrian Smith -- An introduction to European regulatory rights / Sarah Bailey ... [et al.] -- Australia / Wayne Condon -- Canada / Greg Beach ... [et al.] -- China / Lewis Ho -- Denmark / Kasper Frahm, Sture Rygaard -- France / Denis Schertenleib -- Germany / Joachim Feldges, Birgit Kramer -- India / Pravin Anand, Neeti Wilson -- Israel / Liad Whatstein -- Italy / Gualtiero Dragotti, Roberto Valenti -- Japan / Mami Hino -- The Netherlands / Bas Berghuis van Woortman, Mattie de Koning, András Kupecz -- Russia / Alexander Christophoroff ... [et al.] -- Spain / Miquel Montañá -- United Kingdom / Catherine Drew, Sarah Innes, Gareth E Morgan -- United States / Katherine A. Helm, Noah M Leibowitz.
520			_a"In the context of challenging economic circumstances, increasing generic competition and greater pressure on drug pipelines, these are unprecedented times for the life sciences sector. The response from many quarters has been diversification and the movement of business models away from traditional 'blockbuster' small-molecule drugs towards more varied products. However, from university start-ups to the established pharmaceutical giants, the life sciences business still hinges on one simple rule: the need for market exclusivity. Given the difficulty and expense involved in life sciences research, it follows that IP rights, in all their forms, are intricately interwoven with the life sciences. Intellectual Property in the Life Sciences is an exciting new title designed to provide guidance on the IP issues affecting the life sciences sector. It uniquely satisfies two practical needs: a global reach that reflects the worldwide markets within which the life sciences industry now operates, and a sector-based approach addressing the issues that those in the business face. Written by a team of the world's leading specialists in the field, including Lewis Ho from Simmons & Simmons, Joachim Feldges from Field Fisher Waterhouse, Miquel Montana from Clifford Chance and Pravin Anand from Anand and Anand, this accessible guide provides an overview of the key international and European IP legislation, complementing the book's central theme of monopoly protection. In addition, the book features coverage from 15 jurisdictions of the most important and topical life sciences issues on which intellectual property has an impact. Subjects explored within the national chapters include small molecules, secondary patents, DNA, biologicals and personalised medicines, patent infringement and enforcement, compulsory licensing, branding and designs, counterfeiting and collaborative models. This new guide is essential reading for lawyers, in-house counsel and other professionals advising firms in the life science industry"--Provided by publisher.
650		0	_aBiotechnology industries _xLaw and legislation. _912025
650		0	_aBiotechnology industries. _912026
650		0	_aIntellectual property. _912027
700	1		_aEngland, Paul, _d1971- _912028
856	4	1	_3Table of contents only _uhttp://www.loc.gov/catdir/toc/fy12pdf02/2012358826.html
906			_a7 _bibc _ccopycat _d2 _encip _f20 _gy-gencatlg
942			_2ddc _cBK